Tafluprost
Tafluprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure
Mechanism of effect
Prostaglandin analog; exact mechanism by which it reduces IOP is unknown, but it is thought to increase uveoscleral outflow
Pharmacodynamic
Tafluprost acid is a fluorinated prostaglandin F2-alpha analog believed to reduce intraocular pressure by increasing outflow of aqueous humor via the uveoscleral pathway
Pharmacokinetics
Bioavailability: Absorbed through the cornea
Onset: 2-4 hr; peak effect at 12 hr
Peak Plasma Time: 10 minutes
Peak Plasma Concentration: 26 pg/mL
AUC: 394-432 pg•min/mL
Metabolism
Tafluprost is an ester prodrug that is metabolized by hydrolysis to the biologically active acid metabolite (tafluprost acid)
Dosage
drop 0.0015%
Instill 1 drop in affected eye(s) once daily in the evening
Drug contraindications
None
Side effects
Blurred vision , itchy eyes(Conjunctival hyperemia (4-20%
(Ocular stinging (7%
(Ocular pruritus/allergic conjunctivitis (5%
(Cataract (3%
(Growth of eyelashes (2%
(Blurred vision (2%
unoprostone ophthalmic
Alerts
Causes changes to pigmented tissues; most frequently reported changes have been of the iris, eyelid, and eyelashes; pigmentation changes of the iris is likely permanent Increases length, color, thickness, and number of eyelashes
Caution with active intraocular inflammation (may exacerbate condition)
Macular edema reported; caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or with known risk factors for macular edema
Points of recommendation
Instill into conjunctival sac of affected eye
Do not exceed once daily dosing regimen; more frequent administration of prostaglandin analogs may lessen the IOP lowering effect
Reduction of intraocular pressure starts approximately 2 - 4 hours after first administration with maximum effect reached after 12 hr
If other topical ophthalmics are prescribed, each should be administered 5 minutes apart
Preservative free product; use immediately after opening one unit-dose for administration; sterility cannot be maintained after opening
Pregnancy level
Cteratogenic when administered IV in rats and rabbits
Pregnancy Category: C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done
Breast feeding warning
Related drugs
Bimatoprost , Travoprost , Latanoprost , latanoprostene bunod , unoprostone
Latisse
Lumigan
Rescula
Travatan
Travatan Z
unoprostone ophthalmic
Vyzulta
Xalatan
Xelpros
Zioptan
Ask a Pharmacist